RLMD - Relmada Therapeutics, Inc.

Insider activity in RLMD over the last quarter tilts toward buying: insiders added a net 400,000 shares worth roughly $1.7M.

Classified under Biotechnology (Health Care sector), RLMD's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Traversa Sergio	1.50M	$6.15M	-
CFO	Shenouda Maged	1.00M	$4.25M	-
COO	Kelly Paul Edward	502.3K	$1.11M	-
COO	Ence Chuck	403.9K	$888.6K	-

Buys and sells only

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 10, 2026	Shenouda Maged52	Chief Financial Officer	Buy	200,000	$4.22	$843,990.00	+25.0%	-	-
Sep 10, 2026	Traversa Sergio64	Chief Executive Officer	Buy	200,000	$4.14	$828,000.00	+15.4%	-	-
Dec 15, 2025	Traversa Sergio64	Chief Executive Officer	Buy	27,500	$4.12	$113,300.00	+2.2%	+41.7%	-
Dec 15, 2025	Shenouda Maged52	Chief Financial Officer	Buy	11,665	$4.12	$48,059.80	+1.5%	+41.7%	-
Nov 5, 2025	Traversa Sergio64	Chief Executive Officer	Buy	272,500	$2.20	$599,500.00	+27.3%	+51.4%	-
Nov 5, 2025	Ence Chuck	CAO and COO	Buy	136,000	$2.20	$299,200.00	+50.8%	+51.4%	-
Nov 5, 2025	Shenouda Maged52	Chief Financial Officer	Buy	500,000	$2.20	$1,100,000.00	+173.4%	+51.4%	-
Nov 5, 2025	Kelly Paul Edward67	Chief Operating Officer	Buy	90,000	$2.20	$198,000.00	+21.8%	+51.4%	-
Aug 28, 2025	Traversa Sergio64	Chief Executive Officer	Buy	265,976	$0.67	$178,094.99	+36.2%	+440.6%	+458.7%
May 20, 2025	Shenouda Maged52	Chief Financial Officer	Buy	200,000	$0.49	$97,208.00	+226.4%	+11.2%	+1101.0%